Les Szekely, MD
Pulmonary Disease · Doylestown, PANPI 1063526440
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $15,738 of the $18,788 with a category attached, or 83.8%. 51 manufacturers reported payments, led by GSK at 24.8% of the total. Among pulmonary disease clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 830 payments — averaging $22.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$5K
- AstraZeneca$2K
- Regeneron Healthcare Solutions, Inc.$1K
- Harmony Biosciences LLC$1K
- Boehringer Ingelheim$975
- Jazz Pharmaceuticals Inc.$972
- plus $8K from 45 others
Across 29 payments — averaging $6137.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$178K
What the payments were for
- Consulting fees$2,45013%
- Travel & lodging$1051%
- Food & beverage$15,73884%
- Education$4953%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$214
- XYWAV$150
- XYREM$150
How this compares
$18,788 in reported general payments places this provider in the 90th percentile of 703 pulmonary disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 76 | $293,584 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 340 | $266,776 |
| OfevNintedanib Esylate | 17 | $211,780 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 88 | $69,620 |
| Breo ElliptaFluticasone/Vilanterol | 121 | $62,651 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 42 | $26,088 |
| Incruse ElliptaUmeclidinium Bromide | 37 | $22,587 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 24 | $17,860 |
| Spiriva RespimatTiotropium Bromide | 18 | $12,724 |
| EliquisApixaban | 20 | $12,352 |
| SymbicortBudesonide/Formoterol Fumarate | 21 | $10,363 |
| Arnuity ElliptaFluticasone Furoate | 31 | $8,699 |
| DuleraMometasone/Formoterol | 17 | $8,669 |
| Fluticasone-VilanterolFluticasone/Vilanterol | 24 | $8,565 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 34 | $8,377 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $4,657 | $386,800571 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $975 | $242,36459 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $2,092 | $79,983109 claims |
| PfizerEliquis | $194 | $12,35220 claims |
| MerckDulera | $134 | $8,66917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 703 pulmonary disease providers in Pennsylvania.
Other pulmonary disease in Doylestown
- Sandeep Bansaldu Bois$1.4M
- Alan KanouffAltoona$809K
- Gerard CrinerPhiladelphia$657K
- Kenneth LanderUpland$647K
- Richard FriedenheimAbington$627K
- Thomas MeyerWynnewood$615K
- Surya BhattBethlehem$579K
- Tariq CheemaPittsburgh$549K
- Stephen KovacsErie$520K
- Michael ZlupkoAltoona$468K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.